Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05362773 · ClinicalTrials.gov registry record · Phase 1
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
A Phase 1 study of Myelodysplastic Syndromes and Chronic Myeloid Leukemia, sponsored by MacroGenics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 7
- Study locations
NCT05362773 is a Phase 1 study of Myelodysplastic Syndromes and Chronic Myeloid Leukemia that is actively recruiting participants, run by MacroGenics. The registered enrollment target is 130 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (54% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05362773, a Phase 1 study of Myelodysplastic Syndromes and Chronic Myeloid Leukemia, is actively recruiting participants, sponsored by MacroGenics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 7
- Study locations
Study Summary
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Participants will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are met. Response assessments will be performed after Cycle 1 and then after every even numbered cycle starting with Cycle 2 until progression or study treatment discontinuation. Participants will be checked for side effects throughout the study.
Conditions Studied
Interventions
- DRUG MGD024
Study Locations (7)
Colorado
- Colorado Blood Cancer Network - Denver
Maryland
- University of Maryland, Greenbaum Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- START - Midwest - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Duke University Medical Center - Durham
Texas
- South Austin Medical Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05362773
The ClinicalTrials.gov registry entry for NCT05362773 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (54% lower). The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which MGD024 is the first listed.
NCT05362773 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Colorado, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05362773 about?
NCT05362773 is a clinical study titled "A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies". CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokine...
What is the current status of trial NCT05362773?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2022-07-13. Estimated completion is 2027-05.
What conditions does trial NCT05362773 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Classical Hodgkin Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, B-cell.
What interventions are being tested in trial NCT05362773?
The interventions under investigation include: MGD024 (DRUG).
Who is sponsoring clinical trial NCT05362773?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05362773 being conducted?
This trial has 7 study locations across Colorado, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.